ArticleWorld journal of gastroenterology2010
Pro12Ala polymorphism of the peroxisome proliferator-activated receptor γ2 in patients with fatty liver diseases.
Article in World journal of gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Meta-analysis of associations between the peroxisome proliferator-activated receptor-γ Pro12Ala polymorphism and susceptibility to nonalcoholic fatty liver disease, rheumatoid arthritis, and psoriatic arthritis.Genetic testing and molecular biomarkers · 2014Pooled it
- The Pro12Ala polymorphism in the PPAR-γ2 gene is not associated with an increased risk of NAFLD in Iranian patients with type 2 diabetes mellitus.Cellular & molecular biology letters · 2019Article
- Association of SIRT1 gene polymorphism and its expression for the risk of alcoholic fatty liver disease in the Han population.Hepatology international · 2018Article
- Article
- Significance of genetic polymorphisms in patients with nonalcoholic fatty liver disease.Clinical journal of gastroenterology · 2017Review
- Genetic, metabolic and environmental factors involved in the development of liver cirrhosis in Mexico.World journal of gastroenterology · 2015Review
- Genetic background in nonalcoholic fatty liver disease: A comprehensive review.World journal of gastroenterology · 2015Review
- A candidate gene study reveals association between a variant of the Peroxisome Proliferator-Activated Receptor Gamma (PPAR-γ) gene and systemic sclerosis.Arthritis research & therapy · 2015Article
- Systematic review of genetic association studies involving histologically confirmed non-alcoholic fatty liver disease.BMJ open gastroenterology · 2015Article
- Favorable effect of modest alcohol consumption to fatty liver disease.World journal of gastroenterology · 2013Article
- Alcohol consumption and fatty liver disease.World journal of gastroenterology · 2013Article
- Genetic signatures in choline and 1-carbon metabolism are associated with the severity of hepatic steatosis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2013Article
- Peroxisome proliferator-activated receptor genetic polymorphisms and nonalcoholic Fatty liver disease: any role in disease susceptibility?PPAR research · 2013Article
- Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment.Current pharmaceutical design · 2013Article
- The C-681G polymorphism of the PPAR-γ gene is associated with susceptibility to non-alcoholic fatty liver disease.The Tohoku journal of experimental medicine · 2012Article
- Genetic variation in the peroxisome proliferator activated receptor-gamma gene is associated with histologically advanced NAFLD.Digestive diseases and sciences · 2012Article
- Update on pparγ and nonalcoholic Fatty liver disease.PPAR research · 2012Article
- PPARs in Liver Diseases and Cancer: Epigenetic Regulation by MicroRNAs.PPAR research · 2012Article
- Nuclear receptor variants in liver disease.Journal of lipids · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo test the occurrence of the Pro12Ala mutation of the peroxisome proliferator-activated receptor-γ (PPARγ)2-gene in patients with non-alcoholic fatty liver disease (NAFLD) or alcoholic fatty liver disease (AFLD).
methodsDNA from a total of 622 specimens including 259 blood samples of healthy blood donors and 363 histologically categorized liver biopsies of patients with NAFLD (n = 263) and AFLD (n = 100) were analyzed by Real-time polymerase chain reaction using allele-specific probes.
resultsIn the NAFLD and the AFLD collective, 3% of the patients showed homozygous occurrence of the Ala12 PPARγ2-allele, differing from only 1.5% cases in the healthy population. In NAFLD patients, a high incidence of the Ala12 mutant was not associated with the progression of fatty liver disease. However, we observed a significantly higher risk (odds ratio = 2.50, CI: 1.05-5.90, P = 0.028) in AFLD patients carrying the mutated Ala12 allele to develop inflammatory alterations. The linkage of the malfunctioning Ala12-positive PPARγ2 isoform to an increased risk in patients with AFLD to develop severe steatohepatitis and fibrosis indicates a more prominent anti-inflammatory impact of PPARγ2 in progression of AFLD than of NAFLD.
conclusionIn AFLD patients, the Pro12Ala single nuclear polymorphism should be studied more extensively in order to serve as a novel candidate in biomarker screening for improved prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.